bluuebunny/crossref_metadata_2025_split huggingface dataset:
Preventing Mix-Ups between Various Formulations of Amphotericin B; Cardiac Catheterization Lab Error; Say Again?; Colchicine Deaths
Authors: Cohen Michael R. , Smetzer Judy L. 
Published: May 2010

These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices (ISMP). If you have encountered medication errors and would like to report them, you may call USP tollfree, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or United States Pharmacopeia (USP) ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Scheduling of Pharmacist-Provided Medication Education for Hospitalized Patients
Authors: Donihi Amy Calabrese , Yang Eunjin , Mark Scott M. , Sirio Carl A. , Weber Robert J. 
Published: May 2010

Purpose In a comprehensive medication-education program at the University of Pittsburgh Medical Center, pharmacists provide medication education for hospitalized patients at high risk for nonadherence. This study assessed whether patients' ability to recall medication information after hospital discharge was influenced by the timing of education. Methods Patients who received medication education from pharmacists during a 10-week period were included. Patients were called 2 to 3 days after discharge and were asked to recall the indication, name, dose, frequency, and side effects for 2 medications that were reviewed by the pharmacist. After grouping patients by number of days between education and discharge, recall accuracy was compared between the groups. Results Of 270 patients who received education, 100 patients met inclusion criteria and were available for telephone follow-up. The highest recall responses were for frequency of administration (88%), medication name (78%), indication (78%), and dose (75%). In contrast, side effects were accurately recalled by only 34% of the patients. No significant differences were seen between the percentage of patients accurately recalling medication information and the time that education occurred; however, patients educated on the day of discharge tended to recall medication information less accurately. Conclusion Patients educated on the day of discharge did not recall medication information better than those educated prior to the day of discharge. It may be advantageous for medication education to occur 2 to 3 days prior to hospital discharge. Side-effect information was poorly retained; different strategies must be employed to improve patient recall of side effects.
Computer-Based Monitoring as a Tool for Antimicrobial De-Escalation
Authors: Chambers Rachel M. , Wilson John W. , Estes Lynn L. 
Published: May 2010

Purpose Multiple studies have found an association between the prompt initiation of empirically-appropriate antimicrobial therapy and improved patient outcomes. Such empiric-antimicrobial therapy is often broad; however, once the patient's infectious syndrome, microbiology, and susceptibilities are more defined, it is important to refine antimicrobial therapy. Despite the potential benefits of an “antimicrobial de-escalation” approach, it may be difficult to enforce in clinical practice. Mayo Clinic's Computer-Based Antimicrobial Monitoring System (CBAM) is a medical-informatics tool that was used to assist in this endeavor. This study evaluates the hypothesis that CBAM can enhance the de-escalation of vancomycin and broad-spectrum combination antimicrobial therapy. Methods Hospitalized patients at the Mayo Clinic were screened from January through June 2006 using rule-based algorithms incorporated by CBAM. Interventions were performed by physicians and pharmacists as pertinent. These patients were compared with a historical group of patients obtained by CBAM reporting capabilities. De-escalation rates and mean duration of antimicrobial therapy were compared between groups. Results Vancomycin de-escalation rates significantly improved from 33% to 68% with intervention ( P = 0.001). In addition, the average duration of therapy was decreased from 10.4 ± 7.3 days to 7.7 ± 2.4 days among patients who underwent vancomycin de-escalation per recommendation ( P = 0.014). Conclusions Utilizing the Mayo Clinic's CBAM system to identify potential patients for de-escalation is a unique approach and was successful at improving adherence to vancomycin de-escalation.
Sapropterin Dihydrochloride Tablets
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: May 2010

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy & Therapeutics Committee. Subscribers also receive monthly 1-page summary monographs on the agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2008 monograph topics are fosaprepitant dimeglumine injection, thrombin (topical recombinant), etravirine, ciclesonide inhalation aerosol, and tetrabenazine. The DUE is on fosaprepitant dimeglumine injection.
Keeping Patients Safe from Iatrogenic Methadone Overdoses Final Curtain for IV Colchicine Overdoses
Authors: Cohen Michael R. , Smetzer Judy L. 
Published: May 2010

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices (ISMP). If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or United States Pharmacopeia (USP) ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Bosentan: Raynaud Phenomenon
Authors: Generali Joyce , Cada Dennis J. 
Published: May 2010

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of these data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospitalpharmacy@wolterskluwer.com .
Lenalidomide: Behçet Syndrome
Authors: Generali Joyce , Cada Dennis J. 
Published: May 2010

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of these data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospitalpharmacy@wolterskluwer.com .
Medication Errors Associated with Cerebyx; Consumer Safety with Creams and Ointments; Caution Regarding Color-Coded Eye Medications; Strength Misread as Total Dose
Authors: Cohen Michael R. 
Published: May 2010

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices (ISMP). If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or United States Pharmacopeia (USP) ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Sumatriptan Succinate/Naproxen Sodium
Authors: Cada Dennis J. , Levien Terri L. , Baker Danial E. 
Published: May 2010

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2008 monograph topics are on alvimopan, tolvaptan, liraglutide, iclaprim injection, and alogliptin. The DUE is on alvimopan.
Baclofen: Opiate Withdrawal
Authors: Generali Joyce A. , Cada Dennis J. 
Published: May 2010

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature will enable the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. A summary of the most relevant data is provided, including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to hospital pharmacy@wolterskluwer.com .
Contamination Comparison of Transfer Devices Intended for Handling Hazardous Drugs
Authors: Jorgenson James A. , Spivey Susan M. , Au Cam , Canann David , Ritter Howard , Smith Bart 
Published: May 2010

Purpose Heightened awareness of hazardous drug contamination in the workplace has increased the number of marketed, closed-system drug transfer devices (CSTDs). Currently, no official specifications for a closed-system device are available. Therefore, it is important to validate each system against the recommendations given by International Society of Oncology Pharmacy Practitioners and the National Institute for Occupational Safety and Health to make the best decision for an institution. Summary Titanium tetrachloride was selected to simulate the escape of vapor from each product. The second evaluation concentrated on the “dry connections” between the vial and syringe during drug preparation and between the syringe and access port during administration. Fluorescein sodium was selected to simulate contamination with the dry connections between the vial and syringe and between the syringe and access port. Conclusion The 2 studies found that only 1 of the 5 devices tested met the criteria or definition of a CSTD.
Methylnaltrexone Bromide, Subcutaneous
Authors: Cada Dennis J. , Levien Terri L. , Baker Danial E. 
Published: May 2010

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2008 monograph topics are on difluprednate ophthalmic emulsion, eltrombopag, ustekinumab, denosumab, and milnacipran. The DUE is on certolizumab pegol.
Epidural-Intravenous Route Mix-Ups: Reducing the Risk for Deadly Errors; Discontinued Drug Leads to Error
Authors: Smetzer Judy L. , Cohen Michael R. 
Published: May 2010

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the United States Pharmacopeia (USP) Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices (ISMP). If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported through the ISMP ( www.ismp.org ) or USP ( www.usp.org ) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
Economic Impact of Implementing Pneumonia Treatment Guidelines for Intravenous to Oral Conversion
Authors: Emerson Christopher R. , Antonopoulos Marilena S. , Marzella Nino , Grossman Samuel S. 
Published: May 2010

Background Inpatient treatment of pneumonia produces significant costs to the health care system. In an effort to improve quality of care, decrease length of stay, and decrease drug costs associated with treating pneumonia, on October 1, 2006, the Veterans Affairs New York Harbor Healthcare System (VANYHHS) implemented guidelines for treating hospitalized patients with pneumonia. These guidelines included specific criteria for initial selection of an antimicrobial agent based on patient risk factors, conversion from intravenous (IV) to oral antibiotics, and selection of an appropriate oral agent for conversion. The primary objective of this study was assessment of the economic impact of implementing pneumonia treatment guidelines at the VANYHHS. Methods Retrospective analysis of 100 patients admitted to the VANYHHS for treatment of pneumonia was completed before implementation of the guidelines, and then those data were compared with similar data from a group of 100 patients admitted to the hospital for treatment of pneumonia after implementation of the guidelines. Electronic medical records were reviewed for (1) initial antibiotic therapy administered, (2) time needed for conversion from IV to oral antibiotics after becoming eligible for the switch based on implemented guidelines, and (3) length of hospital stay. Results Data from the preguideline group demonstrated that it took an additional 2.31 days to convert patients from IV to oral antibiotics after they were eligible for the switch to oral therapy. The mean length of stay was 9.2 days. Data from the postguideline group illustrated that the time needed to convert patients from IV to oral therapy was decreased to 1.09 days ( P = 0.002) and the mean length of stay was decreased to 8.76 days ( P = 0.677) when compared with the preguideline group data. The estimated annual cost savings from implementing pneumonia treatment guidelines based on the decrease in mean length of stay was $290,482.20 annually. Conclusion Implementing pneumonia treatment guidelines was associated with decreased length of stay and, thus, a decrease in the costs associated with treating pneumonia in an institutional setting. It is estimated that the VANYHHS could save nearly $300,000 annually as a result of the implementation of the treatment guidelines for pneumonia.
Safety and Efficacy of a High-Intensity, Weight-Based, Intravenous Heparin Protocol Revision in Patients who are Obese
Authors: Dee Brian M. , Thomas Michael L. 
Published: May 2010

Purpose Data collected previously within this institution concluded that the initial heparin infusion rate in the high-intensity, weight-based, intravenous (IV) heparin protocol should be adjusted from 18 to 15 units/kg/h (based on actual body weight) in patients who are more than 50% above ideal body weight (IBW). The purpose of this study was evaluation of the safety and efficacy of the revised protocol. Methods A retrospective chart review was conducted from the initiation of the revised protocol on October 28, 2006, through March 15, 2007. All patients receiving high-intensity, weight-based heparin dosing were eligible for inclusion. Outcome measures included percentage of patients achieving therapeutic activated partial thromboplastin time (aPTT), time to first therapeutic aPTT, follow-up aPTT levels, adverse event occurrence, venous thromboembolism recurrence, and influence of concomitant disease states. Results A total of 55 regimens met inclusion criteria. There were no statistically significant differences between patients who were obese (greater than 50% above IBW) and those who were not obese (less than 50% above IBW) with respect to percentage achieving a therapeutic aPTT, time to therapeutic aPTT, or follow-up aPTT values. Patients who were more than 50% above IBW had improved therapeutic anticoagulation parameters postrevision, whereas patients who were 30% to 50% above IBW had worsened therapeutic anticoagulation parameters postrevision. Although the 30% to 50% IBW class had the highest incidence of end-stage renal disease, it appears that the group of patients in this class was overanticoagulated as a whole. Conclusion The institution's revised, high-intensity, weight-based, IV heparin protocol was found safe and effective, validating a potential heparin dosing adjustment for patients who are obese.
Clevidipine Butyrate Injectable Emulsion
Authors: Cada Dennis J. , Levien Terri L. , Baker Danial E. 
Published: May 2010

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2008 monograph topics are on romiplostim, rivaroxaban, golimumab, dronedarone, and degarelix. The DUE is on romiplostim.